Ascendis Pharma A/S (NASDAQ:ASND) Releases Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Ascendis Pharma A/S (NASDAQ:ASND) issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.11, Zacks reports. The company had revenue of $285.45 million during the quarter, compared to the consensus estimate of $362.47 million.

Here are the key takeaways from Ascendis Pharma A/S’s conference call:

• FDA approval of a third TransCon product (YUVIWEL/TransCon CNP) for achondroplasia, with early U.S. uptake of more than 60 children prescribed within weeks and plans for selected international early access and an EU decision expected in Q4 2026.
• Q1 revenue totaled €247M (company cited ~€197M from its lead rare‑endocrine product and €44M from SKYTROFA), with operating profit €25M (10% margin), non‑IFRS net profit €18M, €573M cash on hand, a completed Nasdaq direct listing, redemption of convertible notes, and an agreed PRV sale for $187.5M.
• The Phase II COACH data for the TransCon CNP + TransCon hGH combination showed substantially greater Week‑52 efficacy versus monotherapy (height Z‑score, limb alignment, spinal canal and arm‑span improvements), which management says could reduce or eliminate the need for invasive limb/spine surgeries.
• Management decided to discontinue internal oncology development of TransCon IL‑2 β/γ despite encouraging Phase I/II signals, signaling a strategic pullback from oncology and potential loss of internal upside for that program.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND opened at $231.15 on Thursday. The company has a fifty day simple moving average of $232.16 and a 200 day simple moving average of $224.09. Ascendis Pharma A/S has a 12-month low of $160.86 and a 12-month high of $250.74. The company has a current ratio of 1.00, a quick ratio of 0.72 and a debt-to-equity ratio of 0.79. The company has a market cap of $14.42 billion, a P/E ratio of 26.66 and a beta of 0.39.

Insider Activity

In other news, Director Jean Jacques Bienaime bought 400 shares of the stock in a transaction dated Tuesday, May 26th. The stock was bought at an average price of $237.80 per share, for a total transaction of $95,120.00. Following the completion of the acquisition, the director directly owned 400 shares in the company, valued at approximately $95,120. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Flemming Steen Jensen sold 19,460 shares of the stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $238.49, for a total transaction of $4,641,015.40. The disclosure for this sale is available in the SEC filing. Insiders own 40.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Advisory Services Network LLC purchased a new position in Ascendis Pharma A/S in the third quarter valued at approximately $26,000. Arax Advisory Partners raised its stake in shares of Ascendis Pharma A/S by 212.2% in the fourth quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 104 shares during the period. Global Retirement Partners LLC raised its stake in shares of Ascendis Pharma A/S by 111.9% in the fourth quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 113 shares during the period. GW&K Investment Management LLC lifted its position in shares of Ascendis Pharma A/S by 75.2% during the 4th quarter. GW&K Investment Management LLC now owns 226 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 97 shares during the last quarter. Finally, Quadrant Capital Group LLC bought a new position in Ascendis Pharma A/S during the third quarter worth about $74,000.

Analyst Ratings Changes

A number of research analysts have recently commented on ASND shares. The Goldman Sachs Group reissued a “buy” rating and issued a $255.00 target price on shares of Ascendis Pharma A/S in a report on Monday, March 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $300.00 price target on shares of Ascendis Pharma A/S in a report on Monday, March 2nd. Bank of America upped their price objective on shares of Ascendis Pharma A/S from $262.00 to $292.00 and gave the stock a “buy” rating in a research report on Thursday, April 16th. Evercore reiterated an “outperform” rating and issued a $329.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, May 15th. Finally, Barclays upped their target price on Ascendis Pharma A/S from $342.00 to $345.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $295.39.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.